Clinical trial · Interventional
CP-751,871 Treatment For Patients With Multiple Myeloma
An Open Label Phase I Study Of CP-751,871 In Patients With Multiple Myeloma
NCT01536145CI-TRIAL-00009736completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study represents the first-in-human study for CP-751,871. The study aimed to define the safety, tolerability, and maximum tolerated dose of CP-751,871 in patients with multiple myeloma through a dose escalation design.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CP-751,871 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single agent CP-751,871
- description
- dose escalation design
- interventionNames
- Drug: CP-751,871
Primary outcomes (1)
- measure
- Maximum Tolerated Dose (MTD)
- timeFrame
- Baseline up to Cycle 1 (Week 4 or Week 8)
- description
- The highest dose level at which not more than 1 dose-limiting toxicity (DLT) was observed during Cycle 1 in 6 participants
Secondary outcomes (13)
- measure
- Single Dose End-of-infusion Concentration (Cinf) for CP-751,871
- timeFrame
- 1 hour postdose in Cycle 1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Previously treated multiple myeloma with a quantifiable serum (M spike ≥ 1 g/dL) and/or urine (≥ 200 mg/24-hr) paraprotein * Adequate bone marrow, renal, liver and cardiac function * Eastern Cooperative Oncology Group \[ECOG\] performance status less than or equal to 2 Exclusion Criteria: * Prior allogeneic stem cell transplant (alloSCT) * Myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with CP-751,871 * Prior organ allograft * Concurrent use of insulin, oral hypoglycemic medication, growth hormone (GH), or growth hormone inhibitors * Female patients who are pregnant or lactating
References
Publications (0)
Data not yet available
No reference posted for this study.